Abstract
Drug side effects and ineffectiveness are a source of morbidity, significant disability, and mortality worldwide and increase the overall cost of care. Pharmacogenetics explore a patient’s risk for drug side effects and ineffectiveness and identify the most suitable medication. This research explores cost-effectiveness and potential budget impact on the National Organization for Healthcare Services in Greece (EOPYY), of the iDNA PGx-CNS, an in vitro diagnostic pharmacogenetics test for the treatment of Drug Resistant Depression (DRD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
